Today’s focus is on an emerging new biotech company with potential to make an impact in difficult to…
What can we understand from novel research on the biology of the disease that might lead us to new cancer therapeutics?
Ten intriguing novel agents in early development to watch out for
Reprogramming the tumour microenvironment - can it be done and if so, how and what should be targeted?
In this post we look at an emerging research area that will be important to address if CAR T cell therapy is to be effective in solid tumours
Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines
A look at off Broadway abstracts on early new product development and scientific findings of interest
It's time for an update on new participants to the runners and riders in CLL and NHL. Some interesting findings with BTK inhibitors to consider here!
A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC
How do we go about therapeutically targeting deep protein-protein interactions that can cause aberrant cancer activity? Here's one novel approach in early development...
How do mission critical oncogenes cooperate and act in concert in cancer?
If we want to be able to drug oncogenes such as MYC then we need to figure out how they work and function to find the achilles heel
Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.
Looking under the hood to find biomarkers of response and outcomes, ,
A potential role for epigenetic therapies in straddling the divide between transcription factors and the immune system...
A look at a selection of promising Developmental Therapeutics abstracts from ASH17 - what's in store this year?
The bromodomain market has exploded in recent years with many more agents in the development. Are they all the same though?
Understanding the regulatory circuitry that controls cell state and differentiation may turn out to be groundbreaking research that changes the way we think about targeting and treating cancer.
What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?
Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?
Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.